Olaparib AZD-2281 CAS 763113-22-0 daahirnimada ≥99.0% API Warshada
Nadiif Sarreysa, Wax Soo Saarka Ganacsiga
Olaparib iyo Dhexdhexaadiyeyaasha la xidhiidha:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl) Piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Magaca Kiimikada | Olaparib |
| La mid ah | AZD-2281;KU0059436;Lynparza;4- (3- (4- (cyclopropanecarbonyl)) piperazine-1-carbonyl) -4-fluorobenzyl) phthalazin-1 (2H) -hal;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl) Methyl]-2-fluorobenzoyl]piperazin |
| Lambarka CAS | 763113-22-0 |
| Lambarka CAT | RF-API103 |
| Heerka Saamiyada | Kaydka, Miisaanka Wax-soo-saarka Ilaa boqollaal Kiilogaram |
| Qaanuunka molecular | C24H23FN4O3 |
| Miisaanka Molecular | 434.46 |
| Solubility | Ku milmay DMSO |
| Summada | Kiimikada Ruifu |
| Shayga | Tilmaamaha |
| Muuqashada | Caddaan ilaa budo cad-cad |
| Aqoonsiga 1H NMR | U hoggaansamo qaab-dhismeedka |
| LC-MS | U hoggaansamo qaab-dhismeedka |
| Daahirnimada / Habka Falanqaynta | ≥99.0% (waxaa qoray LC-MS) |
| Qoyaanka (KF) | ≤0.50% |
| Xumaanta Keliya | ≤0.50% |
| Wadarta wasakhda | ≤1.0% |
| Biraha culus (sida Pb) | ≤20pm |
| Heerka Imtixaanka | Heerka Ganacsiga |
| Isticmaalka | API;Joojiyaha PARP |
Xidhmada: Dhalo, Bac aluminium biil ah, Durbaan kartoonada, 25kg/Drum, ama sida waafaqsan shuruudaha macmiilka.
Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka.
Olaparib (CAS: 763113-22-0), awood sare leh oo doorta PARP-horjoogaha.Bishii Disembar 19, 2014, FDA waxay ansixisay daawada novel-ka-hortagga kansarka Olaparib (Lynparza) ee monotherapy loogu talagalay bukaannada kansarka ugxan-sidaha ee sareeyo kaasoo maray ugu yaraan 3 wareeg oo kiimiko ah ama bukaannada looga shakisan yahay isbeddellada BRCA.Isla mar ahaantaana, FDA waxay ansixisay tirada iyo kala soocida xirmooyinka ogaanshaha ee ogaanshaha isbeddellada BRCA1 iyo BRCA2, BRACAnalysis CDx.Olaparib waa dawooyinka ka hortagga PARP ee ugu horreeya oo ay ansixisay FDA.Bishii Febraayo 2, 2015, Maamulka Cuntada iyo Dawooyinka ee Midowga Yurub (EMA) ayaa sidoo kale oggolaaday Olaparib inuu galo suuqa 28 waddan ee Midowga Yurub oo ay ku jiraan Iceland, Liechtenstein iyo Norway.Laakiin calaamadaha EMA iyo FDA ee la ansixiyay wax yar bay ka duwan yihiin;Kan hore waxaa loogu talagalay kiisaska beddelka hidda-wadaha ee BRCA, iyo sidoo kale daaweynta dayactirka loogu talagalay bukaannada kansarka ugxan-sidaha sare ee epithelial ugxan-sidaha kuwaas oo horey u helay daawooyinka kemotherabi ee platinum-ku-jirta oo muujiya jawaab-celinta oo ay ku xiran tahay soo noqoshada.
